Jazz Pharmaceuticals plc — Form 8-K
Filed August 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Jazz Pharmaceuticals reported Q2 2026 total revenues of $1.208 billion (+16% YoY), driven by Xywav ($471M, +13% YoY, 525 net patient adds), Epidiolex ($292M, +16% YoY), and Zepzelca ($106M, +42% YoY). The company raised full-year 2026 revenue guidance to $4.60–$4.75B (from $4.25–$4.50B). Key catalysts: FDA set PDUFA date of August 25, 2026 for zanidatamab in HER2+ 1L gastroesophageal adenocarcinoma; Ziihera generated $15M in Q2; Modeyso (acquired August 2025) contributed $48M. Cash position: $2.2B; debt $4.4B. The company repaid $1.0B in exchangeable notes in June 2026 and generated $824M operating cash flow in H1 2026.
Why this rating
Strong organic growth (+16% revenue) and raised guidance are positive, but event is routine quarterly earnings—not transformational relative to $6.3B market cap. Guidance increase modest (~8–10% midpoint).
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.